Three independent discounted-cash-flow-style models value Anika Therapeutics Inc every trading day. 0 of 3 currently price ANIK above its market price.
| Free Cash Flow model | $-7.66 |
| Excess Profit model | $-28.54 |
| Residual Earnings model | $-2.23 |
| Dividend Discount model | — |
| Piotroski F-Score | 5 / 9 |
| Return on invested capital | -6.5% |
| Net debt / EBITDA | — |
| Gross margin | +56.6% |
| Revenue CAGR | -10.3% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | +2.6% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open ANIK in StockKitty